多发性骨髓瘤治疗热点问题：第56届美国血液学会年会报道

Advances in the treatment of multiple myeloma： reports from the 56th American Society of Hematology annual meeting

多发性骨髓瘤是血液系统第二位常见恶性肿瘤。第56届美国血液学会年会围绕多发性骨髓瘤治疗上的焦点和热点，在五大方面，即新药时代移植的作用及移植的时机、维持治疗、复发难治骨髓瘤患者如何更好得到管理和治疗及新药进展等方面均有精彩呈现。

Multiple myeloma （MM） is the second most common hematological malignancy. In the 56th American Society of Hematology （ASH） annual meeting, there are mainly five hot and key topics focusing on development of MM treatment, including when is the opportunity of transplant-eligible patients in the era of novel therapy？ Should continuous therapy be the standard therapeutic approach in MM？ What is a practical approach to relapsed MM？ How should the recurrence/refractory MM patients be managed and treated？ And what are the approved agents and novel agents？